EPSRC and BBSRC Centre for Doctoral Training in Engineering Solutions for Antimicrobial Resistance
Lead Research Organisation:
UNIVERSITY COLLEGE LONDON
Department Name: London Centre for Nanotechnology
Abstract
Infectious diseases come at a huge societal and economical cost. This has recently been shown by the COVID-19 pandemic. Looking forward, arguably the largest threat is antimicrobial resistance (AMR). As pathogens develop resistance against currently available antimicrobials (e.g., antibiotics) and as the development of new antimicrobials has stalled, we are risking an estimated 10M deaths per year globally and a US$100 trillion costs to the world economy by 2050.
We here propose a Centre for Doctoral Training on Engineering Solutions for Antimicrobial Resistance, with the overall aim of training physical scientists and engineers with the specialist research skills as well as broad contextual skills to create rapid impact targeting the AMR challenge. This includes different disciplines and wider aspects such as commercialisation/translation, public-health context, regulation and standardisation, implementation and adoption, public awareness and perception, and communication.
Identifying key research areas that depend on cutting-edge research advances in engineering and physical sciences, our Centre for Doctoral Training focuses on preventing the spread of infection, on surveillance and diagnostics, and on antimicrobial and vaccine development. By designing and delivering our training programme with public health institutions, multinational businesses, SMEs and charities, we maximise the impact of such research on addressing the public health threat of AMR and on exploiting business opportunities that are also associated with solutions to it.
We here propose a Centre for Doctoral Training on Engineering Solutions for Antimicrobial Resistance, with the overall aim of training physical scientists and engineers with the specialist research skills as well as broad contextual skills to create rapid impact targeting the AMR challenge. This includes different disciplines and wider aspects such as commercialisation/translation, public-health context, regulation and standardisation, implementation and adoption, public awareness and perception, and communication.
Identifying key research areas that depend on cutting-edge research advances in engineering and physical sciences, our Centre for Doctoral Training focuses on preventing the spread of infection, on surveillance and diagnostics, and on antimicrobial and vaccine development. By designing and delivering our training programme with public health institutions, multinational businesses, SMEs and charities, we maximise the impact of such research on addressing the public health threat of AMR and on exploiting business opportunities that are also associated with solutions to it.
Organisations
- UNIVERSITY COLLEGE LONDON (Lead Research Organisation)
- Amazon Web Services EMEA SARL (Project Partner)
- Great Ormond Street Hospital (Project Partner)
- Oxford Nanopore Technologies (Project Partner)
- NIHR Biomedical Research Centre at UCLH (Project Partner)
- Phico Therapeutics Ltd (Project Partner)
- National Biofilms Innovation Centre (Project Partner)
- Ideal Standard (UK) Ltd (Project Partner)
- National Physical Laboratory NPL (Project Partner)
- Dyson Limited (Project Partner)
- 1928 Diagnostics AB (Project Partner)
- Bonalive Biomaterials Ltd (Project Partner)
- UK Health Security Agency (Project Partner)
- UK BioIndustry Association (BIA) (Project Partner)
- Medicines and Healthcare products Regulatory Agency (MHRA) (Project Partner)
- Royal National Orthopaedic Hosp NHS Tr (Project Partner)
- Procter & Gamble Limited (P&G UK) (Project Partner)
- The Francis Crick Institute (Project Partner)
- Test Labs Ltd (Project Partner)
